Prosecution Insights
Prosecution Insights
35 pending office actions • 3 clients • 27 examiners • 13 art units • 0 of 35 (0%) have an AI response strategy ready • 35 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 16 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 16 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 15 (43%) |
| §103 only | 9 (26%) |
| §112 only | 1 (3%) |
| Double-patenting + other | 2 (6%) |
| Multi-statute (no §101) | 8 (23%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, NAM P | 3 | 54.7% | +47.4% |
| LIRIANO-NG, MELISSA LIZETTE | 2 | — | — |
| DUNN, MCKENZIE A | 2 | 53.8% | +55.3% |
| COUNTS, GARY W | 2 | 59.1% | +29.7% |
| FRITCHMAN, REBECCA M | 2 | 45.7% | +35.8% |
| MARCSISIN, ELLEN JEAN | 2 | 33.8% | +50.0% |
| IVICH, FERNANDO NMN | 2 | 44.1% | +71.5% |
| SALEH, ZAID MUHAMMAD | 1 | 67.3% | +45.0% |
| DOWNING, SAVANNAH STARR | 1 | 78.6% | +4.4% |
| TIMILSINA, SHARAD | 1 | 76.3% | +14.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17891458 | IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING | MARCSISIN, ELLEN JEAN | 51d overdue |
| 18556849 | INFORMATION PROCESSING DEVICE FOR PROVIDING REFERENCE INFORMATION RELATING TO DIAGNOSIS OF THYROID DISEASE | HRANEK, KAREN AMANDA | 25d overdue |
| 17575120 | S100A9 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ENDOMETRIOSIS | IVICH, FERNANDO NMN | 19d overdue |
| 17162140 | Use of Biomarkers in the Assessment of the Early Transition from Arterial Hypertension to Heart Failure | MARCSISIN, ELLEN JEAN | 19d overdue |
| 18561621 | sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS | COUNTS, GARY W | 8d overdue |
| 17575137 | SUBSTANCE P AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ENDOMETRIOSIS | IVICH, FERNANDO NMN | 2d overdue |
| 17907039 | CORONA NUCLEOCAPSID ANTIGEN FOR USE IN ANTIBODY-IMMUNOASSAYS | JOHANSEN, PETER N. | 8d |
| 18337018 | LC-MS METHOD FOR DETECTING AND QUANTIFYING 11-OXYGENATED STEROIDS | SODERQUIST, ARLEN | 21d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17891458 | IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING | MARCSISIN, ELLEN JEAN | 51d overdue |
| 17575120 | S100A9 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ENDOMETRIOSIS | IVICH, FERNANDO NMN | 19d overdue |
| 17162140 | Use of Biomarkers in the Assessment of the Early Transition from Arterial Hypertension to Heart Failure | MARCSISIN, ELLEN JEAN | 19d overdue |
| 18561621 | sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS | COUNTS, GARY W | 8d overdue |
| 17575137 | SUBSTANCE P AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ENDOMETRIOSIS | IVICH, FERNANDO NMN | 2d overdue |
| 18306195 | DETECTION OF AN ANALYTE OF INTEREST BY NANOESI MASS SPECTROMETRY | FRITCHMAN, REBECCA M | 21d |
| 17772959 | SEPSIS MANAGEMENT | COUNTS, GARY W | 29d |
| 18935834 | METHOD AND LABORATORY SYSTEM FOR DETERMINING AT LEAST ONE CONTAINER INFORMATION ABOUT A LABORATORY SAMPLE CONTAINER | SALEH, ZAID MUHAMMAD | — |
| Client (Assignee) | Pending OAs |
|---|---|
| ROCHE DIAGNOSTICS OPERATIONS, INC. | 33 |
| Roche Diagnostics Operations, Inc. | 1 |
| ROCHE SEQUENCING SOLUTIONS, INC. | 1 |
| Art Unit | Apps |
|---|---|
| 1678 | 11 |
| 1797 | 3 |
| 1758 | 3 |
| 1677 | 3 |
| 1675 | 2 |
| 2884 | 1 |
| 1652 | 1 |
| 3684 | 1 |
| 1796 | 1 |
| 2881 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18935834 | METHOD AND LABORATORY SYSTEM FOR DETERMINING AT LEAST ONE CONTAINER INFORMATION ABOUT A LABORATORY SAMPLE CONTAINER | Roche Diagnostics Operations, Inc. | SALEH, ZAID MUHAMMAD | §103 | Non-Final OA | — | Pending | Nov 04, 2024 | |
| 18645358 | ON-BOARD CONJUGATION | Roche Diagnostics Operations, Inc. | LIRIANO-NG, MELISSA LIZETTE | §103 | Non-Final OA | — | Pending | Apr 24, 2024 | |
| 18620273 | LIGHT SOURCE FOR GENERATING ILLUMINATION LIGHT | Roche Diagnostics Operations, Inc. | DOWNING, SAVANNAH STARR | 2884 | §103 | Final Rejection | 39d | Pending | Mar 28, 2024 |
| 18689808 | METHOD FOR AUTOMATED QUALITY CHECK OF CHROMATOGRAPHIC AND/OR MASS SPECTRAL DATA | Roche Diagnostics Operations, Inc. | TIMILSINA, SHARAD | §101§102§103 | Non-Final OA | — | Pending | Mar 06, 2024 | |
| 18541476 | METHOD FOR IMMUNOSENSING ON A LIPID LAYER | Roche Diagnostics Operations, Inc. | DUNN, MCKENZIE A | §102§103DP | Non-Final OA | — | Pending | Dec 15, 2023 | |
| 18541708 | METHOD FOR IMMUNOSENSING ON A LIPID LAYER USING MAGNETIC TUNNEL JUNCTIONS II | Roche Diagnostics Operations, Inc. | DUNN, MCKENZIE A | §101§103§112Other | Non-Final OA | — | Pending | Dec 15, 2023 | |
| 18561621 | sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS | Roche Diagnostics Operations, Inc. | COUNTS, GARY W | 1678 | §101§102§103§112 | Final Rejection | 8d overdue | Pending | Nov 16, 2023 |
| 18557895 | GDF15 MARKER PANELS FOR EARLY DETECTION OF SEPSIS | Roche Diagnostics Operations, Inc. | MOAZZAMI, NAGHMEH NINA | 1652 | §101§103§112DPOther | Non-Final OA | 61d | Pending | Oct 27, 2023 |
| 18556849 | INFORMATION PROCESSING DEVICE FOR PROVIDING REFERENCE INFORMATION RELATING TO DIAGNOSIS OF THYROID DISEASE | Roche Diagnostics Operations, Inc. | HRANEK, KAREN AMANDA | 3684 | §101§103 | Final Rejection | 25d overdue | Pending | Oct 23, 2023 |
| 18339799 | METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE | Roche Diagnostics Operations, Inc. | NGUYEN, NAM P | 1678 | §103§112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18339760 | AUTOMATED CLINICAL DIAGNOSTIC SYSTEM AND METHOD | Roche Diagnostics Operations, Inc. | WALLENHORST, MAUREEN | 1797 | §102§103§112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18337018 | LC-MS METHOD FOR DETECTING AND QUANTIFYING 11-OXYGENATED STEROIDS | Roche Diagnostics Operations, Inc. | SODERQUIST, ARLEN | 1797 | §102§103§112 | Final Rejection | 21d | Pending | Jun 18, 2023 |
| 18333347 | INTERFERENCE MONITORING FOR PROVIDING A VERIFIED ANALYTE MEASUREMENT | Roche Diagnostics Operations, Inc. | HYUN, PAUL SANG HWA | 1796 | §101§102§103§112 | Final Rejection | 33d | Pending | Jun 12, 2023 |
| 18328104 | DETECTION OF AN ANALYTE OF INTEREST BY CROSS SPRAY ESI MASS SPECTROMETRY | Roche Diagnostics Operations, Inc. | STOFFA, WYATT A | 2881 | §103 | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18312442 | DERIVATIZATION OF AT LEAST ONE ANALYTE OF INTEREST FOR MASS SPEC MEASUREMENTS IN PATIENT SAMPLES | Roche Diagnostics Operations, Inc. | XU, XIAOYUN | 1797 | §103 | Final Rejection | 2d overdue | Pending | May 04, 2023 |
| 18306195 | DETECTION OF AN ANALYTE OF INTEREST BY NANOESI MASS SPECTROMETRY | Roche Diagnostics Operations, Inc. | FRITCHMAN, REBECCA M | 1758 | §103 | Non-Final OA | 21d | Pending | Apr 24, 2023 |
| 18028235 | CIRCULATING TOTAL-NT-PROBNP (GLYCOSYLATED AND UNGLYCOSYLATED NT-PROBNP) AND ITS RATIO WITH NT-PROBNP (UNGLYCOSYLATED NT-PROBNP) IN THE ASSESSMENT OF ATRIAL FIBRILLATION | Roche Diagnostics Operations, Inc. | FRITCHMAN, REBECCA M | 1758 | §101§103 | Final Rejection | — | Pending | Mar 24, 2023 |
| 18124837 | COMPUTER-IMPLEMENTED METHOD FOR DETECTING AT LEAST ONE INTERFERENCE AND/OR AT LEAST ONE ARTEFACT IN AT LEAST ONE CHROMATOGRAM | Roche Diagnostics Operations, Inc. | ISHIZUKA, YOSHIHISA | 2857 | §103§112 | Final Rejection | — | Pending | Mar 22, 2023 |
| 18021085 | IGFBP7 FOR THE ASSESSMENT OF SILENT BRAIN INFARCTS AND COGNITIVE DECLINE | Roche Diagnostics Operations, Inc. | WEIDNER, ADAM M | 1675 | §101§103§112 | Non-Final OA | — | Pending | Feb 13, 2023 |
| 18017073 | GDF-15 FOR PREDICTING THE DISEASE SEVERITY OF A PATIENT WITH COVID-19 | Roche Diagnostics Operations, Inc. | ZOU, NIANXIANG | 1671 | §103 | Final Rejection | 61d | Pending | Jan 19, 2023 |
| 17907039 | CORONA NUCLEOCAPSID ANTIGEN FOR USE IN ANTIBODY-IMMUNOASSAYS | Roche Diagnostics Operations, Inc. | JOHANSEN, PETER N. | 1644 | §103§112 | Final Rejection | 8d | Pending | Sep 22, 2022 |
| 17801469 | DETECTION METHOD OF CIRCULATING BMP10 (BONE MORPHOGENETIC PROTEIN 10) | Roche Diagnostics Operations, Inc. | GAO, ASHLEY HARTMAN | 1678 | §112 | Non-Final OA | — | Pending | Aug 22, 2022 |
| 17891458 | IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING | Roche Diagnostics Operations, Inc. | MARCSISIN, ELLEN JEAN | 1677 | §101§103§112 | Final Rejection | 51d overdue | Pending | Aug 19, 2022 |
| 17745429 | DERIVATIZATION OF BETA-LACTAM ANTIBIOTICS FOR MASSSPEC MEASUREMENTS IN PATIENT SAMPLES | Roche Diagnostics Operations, Inc. | SVEIVEN, MICHAEL CAMERON | 1678 | §103Other | Non-Final OA | — | Pending | May 16, 2022 |
| 17772959 | SEPSIS MANAGEMENT | Roche Diagnostics Operations, Inc. | COUNTS, GARY W | 1678 | §101§103 | Non-Final OA | 29d | Pending | Apr 28, 2022 |
| 17660299 | PREANALYTIC SYSTEM FOR PREPARING A LABORATORY SAMPLE CONTAINER | Roche Diagnostics Operations, Inc. | CHIU, MAY LEUNG | 1758 | §102§103§112 | Non-Final OA | — | Pending | Apr 22, 2022 |
| 17575120 | S100A9 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ENDOMETRIOSIS | Roche Diagnostics Operations, Inc. | IVICH, FERNANDO NMN | 1678 | §101§103§112Other | Non-Final OA | 19d overdue | Pending | Jan 13, 2022 |
| 17575202 | S100A12 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ENDOMETRIOSIS | Roche Diagnostics Operations, Inc. | MONTGOMERY, ANN Y | 1678 | §101§103§112 | Non-Final OA | 28d | Pending | Jan 13, 2022 |
| 17575137 | SUBSTANCE P AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ENDOMETRIOSIS | Roche Diagnostics Operations, Inc. | IVICH, FERNANDO NMN | 1678 | §101§103§112 | Non-Final OA | 2d overdue | Pending | Jan 13, 2022 |
| 17350822 | METHODS FOR DETECTING AN ANALYTE USING STRUCTURE SWITCHING BINDING AGENTS | Roche Sequencing Solutions, Inc. | LIRIANO-NG, MELISSA LIZETTE | 1677 | §102§103 | Final Rejection | — | Pending | Jun 17, 2021 |
| 17162140 | Use of Biomarkers in the Assessment of the Early Transition from Arterial Hypertension to Heart Failure | Roche Diagnostics Operations, Inc. | MARCSISIN, ELLEN JEAN | 1677 | §101§103§112 | Final Rejection | 19d overdue | Pending | Jan 29, 2021 |
| 17150504 | METHODS OF IDENTIFYING AN INDIVIDUAL AS HAVING OR BEING AT RISK OF DEVELOPING AN AMYLOID-POSITIVE DEMENTIA BASED ON MARKER MOLECULES AND RELATED USES | Roche Diagnostics Operations, Inc. | RAMADAN, OMAR | 1678 | §101§102§103§112 | Final Rejection | — | Pending | Jan 15, 2021 |
| 16931599 | HYPERCROSSLINKING WITH DIAMINE CROSSLINKERS | Roche Diagnostics Operations, Inc. | NGUYEN, NAM P | 1678 | §103§112 | Final Rejection | — | Pending | Jul 17, 2020 |
| 16825181 | MULTIVALENT MONO- OR BISPECIFIC RECOMBINANT ANTIBODIES FOR ANALYTIC PURPOSE | Roche Diagnostics Operations, Inc. | ESSEX, LAURA ANN | 1675 | §103 | Final Rejection | — | Pending | Mar 20, 2020 |
| 16599480 | SUPERPARAMAGNETIC AND HIGHLY POROUS POLYMER PARTICLES FOR DIAGNOSTIC APPLICATIONS | Roche Diagnostics Operations, Inc. | NGUYEN, NAM P | 1678 | §103§112DP | Final Rejection | — | Pending | Oct 11, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial